NTRC Precision Medicine Services puts its cell-based profiling offers in the spotlight on the new website www.oncolines.com.
The website focuses on NTRC’s cancer cell line profiling, bioinformatics and cell-based assay development services. Cell proliferation assays and bioinformatics are covered as unique items under the brand name Oncolines™ and can now be ordered separately. Bioinformatics is offered for Oncolines™ data as well as your internal cell proliferation results. Combination studies can be found under SynergyFinder™. Mechanistic Cell Biology describes cell-based assay development for target validation and compound profiling in primary patient samples.
Proliferation assays in cancer cell lines are widely applied in drug discovery projects to screen drug efficacy. Screens may cover a large cancer cell line panel to obtain an unbiased view of your compound’s activity and selectivity. Studies can also be run on a selection of cell lines, for instance cell lines that are known for high expression of your target. Oncolines™ cell lines are within 10 passages from the original ATCC vial. Dose response curves are generated on the basis of 9 dilution points in duplicate. The proliferation results can distinguish cytotoxic from cytostatic effects. And, most importantly, data are generated with high reproducibility.
Bioinformatics analysis investigates drug sensitivity markers for your compound using the response parameters of cancer cell line profiling, without the need for additional experiments. We perform analysis on IC50 values and gene mutation data to identify genomic drug response biomarkers for cancer. Case studies have confirmed patient stratification markers that have been used in the clinic.
SynergyFinder™ helps to ensure that new therapies are combined in the best way possible. Many cancer therapies are applied in combination. To identify the right partner of your lead compound with standards of care or new drugs, NTRC has developed SynergyFinder™. The studies are scalable from 1 to 1,000 combinations and consist of full dose response testing of single agents and mixtures. Fixed Ratio experiments allow precise IC50 based scoring of synergy, Loewe-based synergy is determined by experimentally determined curve shift and CI Index (Chou-Talalay equation). IC50 profiles of more than 160 standards of care and experimental therapeutics are available to propose mixtures.
Mechanistic Cell Biology
Sound in vitro mechanism of action data are needed to progress your compound towards the clinic. The right assay format is determined by your anti cancer drug candidate and its target. We support you in determining the effects of your compound on selected biological pathways. A typical workflow consists of 1. selection of cell lines on the basis of expression of the target or tissue type; 2. generation of knockdown cell lines; 3. screening of drug activity in the most suitable assay; 4. confirmation in primary material.